Hwail Pharmaceutical Co.Ltd (061250) — Capital Reinvestment Ratio
Latest as of September 2025:
0.20x
Hwail Pharmaceutical Co.Ltd (061250) has a Capital Reinvestment Ratio of 0.20x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩6.82 Billion) in capital expenditures (₩1.39 Billion). See cash generation quality of Hwail Pharmaceutical Co.Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.20x
Capex / Operating Cash Flow
Operating Cash Flow
₩6.82 Billion
KRW
Capital Expenditures
₩1.39 Billion
KRW
Data as of
Sep 2025
Most recent filing
Hwail Pharmaceutical Co.Ltd Capital Reinvestment Ratio (2011–2024)
This chart tracks Hwail Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year Capital Reinvestment Ratio for Hwail Pharmaceutical Co.Ltd from 2011 to 2024. For live market cap and broader valuation context, see 061250 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.98x | ₩11.63 Billion | ₩34.63 Billion | ▲ +894.9% |
| 2023 | 0.30x | ₩7.02 Billion | ₩2.10 Billion | ▲ +143.3% |
| 2021 | 0.12x | ₩20.09 Billion | ₩2.47 Billion | ▼ -58.2% |
| 2019 | 0.29x | ₩3.69 Billion | ₩1.09 Billion | ▲ +36.1% |
| 2018 | 0.22x | ₩7.17 Billion | ₩1.55 Billion | ▲ +250.9% |
| 2017 | 0.06x | ₩8.34 Billion | ₩513.62 Million | ▲ +42.9% |
| 2016 | 0.04x | ₩9.58 Billion | ₩413.00 Million | ▼ -96.7% |
| 2013 | 1.32x | ₩6.97 Billion | ₩9.18 Billion | ▼ -82.9% |
| 2012 | 7.69x | ₩1.00 Billion | ₩7.72 Billion | ▲ +1034.5% |
| 2011 | 0.68x | ₩7.86 Billion | ₩5.32 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow